Pfizer
NEWS
Biopharma has been stepping up research and drug development against COVID-19 -though results haven’t always been encouraging. Here are the latest stories from this space:
MorphoSys is having a busy week after entering into an equity participation agreement with HIBio and a supply agreement and clinical collaboration with Pfizer and Incyte.
Dren Bio announced the completion a of $65M Series B financing round. New investors include Pfizer, ArrowMark Partners and Revelation Partners.
MorphoSys U.S. Inc., Pfizer and Incyte are teaming up to test Pfizer’s TTI-622 in conjunction with Monjuvi plus lenalidomide in patients with lymphoma.
While a handful of companies have dominated the COVID-19 vaccine market in the U.S. and Europe, a number of biotechs are continuing to develop vaccines to use as booster shots.
GSK reported positive headline data from a pre-specified efficacy interim analysis of the Phase III trial of its RSV vaccine.
The FDA plans to review changes to Novavax’s manufacturing process before it authorizes its vaccine.
On Tuesday, the FDA’s Vaccines and Related Biological Products Advisory Committee voted 21-0 with one abstention to recommend authorization of Novavax’s COVID-19 vaccine.
Ibrance, a first-line treatment for ER+, HER2 - metastatic breast cancer, did not improve the overall survival rate in patients. Read on to know more.
JOBS
IN THE PRESS